Date: 2014-10-16
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago
Company: Acucela (USA - WA)
Product: emixustat hydrochloride
Action mechanism:
Disease: geographic atrophy
Therapeutic area: Ophtalmological diseases
Country:
Trial details:
Latest
news: * On October 16, 2014, Acucela, a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced that results on the pharmacodynamic properties of emixustat hydrochloride in patients with geographic atrophy will be presented by Roger L. Novack, MD, PhD, Retina-Vitreous Associates Medical Group, Beverly Hills, California, during a podium session at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago. The abstract can be accessed at: http://www.aao.org/meetings/annual_meeting/program/. The presentation is entitled “Pharmacodynamic Properties of Emixustat Hydrochloride in the Treatment of Geographic Atrophy (PA089).” Emixustat, the first internally developed investigational compound by Acucela, is orally dosed, targets the visual cycle, and is in development for the treatment of GA associated with dry AMD. Dr. Novack was one of the investigators in Acucela’s Phase 2a clinical study and is currently participating as an investigator in the Phase 2b/3 “SEATTLE” study.
